Vertex Pharma’s Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence
In Phase 1/2 results for 12 patients at least one year after receiving the cell therapy, zimislecel, Vertex Pharmaceuticals reported all participants achieved blood glucose in the target range and 10 of the 12 were free of exogenous insulin as of the data cutoff. Vertex expects to complete enrollment in the pivotal portion of the study this summer, paving the way for potential regulatory submissions next year. The post Vertex Pharma’s Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence appeared first on MedCity News.
In Phase 1/2 results for 12 patients at least one year after receiving the cell therapy, zimislecel, Vertex Pharmaceuticals reported all participants achieved blood glucose in the target range and 10 of the 12 were free of exogenous insulin as of the data cutoff. Vertex expects to complete enrollment in the pivotal portion of the study this summer, paving the way for potential regulatory submissions next year.
The post Vertex Pharma’s Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence appeared first on MedCity News.
